Microenvironment changes induced by Endostar monotherapy in patients with non-small cell lung cancer: a pilot study

沈钰新; 赵伟新; 王升平

doi:10.3969/j.issn.1007-3969.2015.10.011

您当前的位置：

首页 >

文章列表页 >

Microenvironment changes induced by Endostar monotherapy in patients with non-small cell lung cancer: a pilot study

更新时间：2025-12-31

- Microenvironment changes induced by Endostar monotherapy in patients with non-small cell lung cancer: a pilot study
- China Oncology Vol. 25, Issue 10, Pages: 817-822(2015)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学附属肿瘤医院放射诊断科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.10.011
  CLC：
- Published Online：17 December 2015，
  
  Published：17 December 2015
- 稿件说明：
移动端阅览
沈钰新,赵伟新,王升平,等. 重组人血管内皮抑制素单药对非小细胞肺癌肿瘤血管微环境影响的初步研究[J]. 中国癌症杂志, 2015, 25(10): 817-822.

沈钰新, 赵伟新, 王升平. Microenvironment changes induced by Endostar monotherapy in patients with non-small cell lung cancer: a pilot study[J]. China Oncology, 2015, 25(10): 817-822.
沈钰新,赵伟新,王升平,等. 重组人血管内皮抑制素单药对非小细胞肺癌肿瘤血管微环境影响的初步研究[J]. 中国癌症杂志, 2015, 25(10): 817-822. DOI： 10.3969/j.issn.1007-3969.2015.10.011.

沈钰新, 赵伟新, 王升平. Microenvironment changes induced by Endostar monotherapy in patients with non-small cell lung cancer: a pilot study[J]. China Oncology, 2015, 25(10): 817-822. DOI： 10.3969/j.issn.1007-3969.2015.10.011.

摘要

背景与目的：临床数据显示对于局部晚期或晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)，重组人血管内皮抑制素(恩度)联合放疗或化疗较传统化放疗可能更具优势，但其机制，特别是对血管微环境的影响依旧不甚明确。该研究通过CT灌注成像技术(dynamic contrast-enhanced perfusion computed tomography，CT perfusion)对NSCLC肿瘤局部血流灌注进行定量分析，评估恩度单药对NSCLC肿瘤血管微环境的影响。方法：经细胞学或组织学确认的初治Ⅲ

/Ⅳ期NSCLC患者可入组本研究。全部患者接受7.5 mg⁄m

恩度单药治疗14 d，于基线期及治疗后分别接受CT灌注成像检查，获取灌注图像并定量分析血流灌注参数：血流量(blood flow，BF)、血容量(blood volume，BV)以及血管表面通透性(permeability surface，PS)。结果：7例患者(4例为Ⅲ

期，3例为Ⅳ期)入组，均完成基线期及恩度单药治疗后CT灌注扫描。血流灌注参数BF、BV、PS的中位值于治疗前后分别为27.1/48.9 mL·(100 mL·min)-1、86.8/84.8 mL·100 mL

-1

以及45.0/54.0 mL·(100mL·min)

-1

。经过14 d恩度单药治疗，肿瘤BF值较治疗前显著上升(P=0.028)，而BV值与PS值变化无统计学意义(BV：P=0.398；PS：P=0.237)。结论：恩度单药治疗局部晚期或晚期NSCLC后，可导致肿瘤局部灌注血流量明显上升而通透性和血容量则变化不明显。

Abstract

Background and purpose: Clinical data show that Endostar

a recombinant human endostatin

has the therapeutic benefit for patients with non-small cell lung cancer (NSCLC) while combined with chemotherapy or radiotherapy. However

the microenvironment changes induced by Endostar monotherapy in NSCLC is not yet clear. The purpose of this study was to prospectively study tumor vascular effects of Endostar monotherapy in patients wi

th locally advanced or advanced NSCLC by dynamic contrast-enhanced perfusion computed tomography (CT perfusion

CT-p). Methods: Previously untreated patients with histologically or cytologically confirmed locally advanced or advanced NSCLC were eligible. All patients received daily Endostar (7.5 mg⁄m

) for 14 days. CT-p scans were acquired at the baseline and post-treatment. CT-p parameters

such as blood flow (BF)

blood volume (BV) and permeability surface PS (area product)

were measured in all patients. Results: Of all 7 patients enrolled

four were staged as ⅢB and three as stage Ⅳ (2 with malignant pleural effusion

1 with brain metastasis). The median BF

BV and PS values of baseline and post-treatment were 27.1/48.9 mL/100 mL/min

86.8/84.8 mL/100 mL and 45.0/54.0 mL/100 mL/min

respectively. After administration of Endostar for 14 days

BF showed a significant increase compared with that at baseline (P=0.028)

whereas no significant changes were found in BV (P=0.398) and PS (P=0.237) values. Conclusion: Our results suggest that Endostar monotherapy induces a significant increase in BF whereas no significant difference in BV and PS.

关键词

Keywords

references

Views

1570

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Important clinical research progress in lung cancer in 2022

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Related Author

Qiling DENG

Di SONG

Kexin XI

Xiaoting XIE

Xiaoyan WU

Wei ZHAO

Yicong LIN

Yue WANG

Related Institution

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Peking University International Hospital

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

AI问答

⁰